Safimaltib

N/A

Report date: 2022/03/01 14:28:13
NME

Base Information

Drug NameSafimaltib
Drug Alias NameJNJ-6633JNJ-67856633
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitors
TargetsMucosa-associated lymphoid tissue lymphoma translocation protein 1
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[22] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen Research & Development LlcCatalent (Shanghai) Clinical Trial Supplies Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A